Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DSGN vs FHTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DSGN Captures Overall Composite Edge (49.9 HOLD vs 38.2 SELL), While FHTX Leads 6–0 on Growth & Valuation Pillars

DSGN Overall Winner 6-Pillar Tally: DSGN 0 – 6 FHTX Matrix Metrics: DSGN 5 – 4 FHTX

As of Nov 16, 2026, Design Therapeutics, Inc. (DSGN) captures the overall head-to-head institutional edge over Foghorn Therapeutics Inc. (FHTX) on higher Unified Composite conviction (49.9/100 HOLD vs. 38.2/100 SELL) after splitting the core matrix 5–4 (led by composite factor balance), while FHTX wins 6–0 across the 6-pillar growth and valuation breakdown. DSGN trades at $9.94 (N/M Forward P/E, 0.0% operating margin) versus FHTX at $1.81 (N/M Forward P/E, 8.0% operating margin).

  • Growth vs. Quality Trade-Off: DSGN earns the overall head-to-head edge with a stronger Unified Composite Score (49.9/100 HOLD vs. FHTX 38.2/100 SELL) and 1.32β · 61% Vol risk profile, whereas FHTX leads top-line expansion (+924.7% YoY revenue growth, N/M PEG, and 6 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile FHTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DSGN vs FHTX
DSGN NASDAQ Head-to-Head Winner
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
TTM Revenue $33,000
Forward P/E N/M
Beta / 30D Vol 1.32β · 61% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $10.53 · SMA50: $11.59
FHTX NASDAQ
Foghorn Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$1.81
-12.56% 1D
Market Cap $122.9M
TTM Revenue $64M
Forward P/E N/M
Beta / 30D Vol 1.67β · 79% Vol
Unified Composite Score
38.2 / 100 SELL
Tech 25.0 Fund 47.0 Flow 50.0 Mom 74.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -38.5%), weak momentum, RSI 37
RSI-14: 36.9 · SMA20: $2.03 · SMA50: $2.73

6-Pillar Scorecard Institutional Category Breakdown (DSGN 0 – 6 FHTX)

Columns: Metric · DSGN · FHTX
1. Valuation Multiples FHTX
Forward P/E N/M N/M
Trailing P/E N/M 22.8x
PEG Ratio N/M N/M
EV / Revenue N/M 1.9x
2. Growth & Scale FHTX
Revenue Growth (YoY) +0.0% +924.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $33,000 $64M
Market Cap $677.5M $122.9M
3. Profitability & Quality FHTX
Gross Margin N/A 30.7%
Operating Margin 0.0% 8.0%
Net Profit Margin 0.0% 8.4%
Return on Equity (ROE) -36.9% -470.4%
4. Balance Sheet & Cash Flow FHTX
Cash Generation (TTM) -$59M $6.0M EBITDA
Cash Flow Margin N/A 9.3% EBITDA Mgn
Net Cash / Leverage $13M Net Cash -470.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FHTX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 92.0% (13th %ile) 164.9% (34th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat FHTX
OpEx & R&D Intensity N/A 22.7% of Rev ($15M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DSGN (5) vs FHTX (4)
Institutional Metric DSGN FHTX Criterion Row Edge
Market Capitalization
Scale
$677.5M $122.9M Larger Scale DSGN
Trailing P/E Ratio
Valuation
N/M 22.8x Lower Multiple FHTX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +924.7% Higher Growth FHTX
Operating Margin (TTM)
Profitability
0.0% 8.0% Higher Margin FHTX
Net Profit Margin
Profitability
0.0% 8.4% Higher Margin FHTX
Return on Equity (ROE)
Capital Efficiency
-36.9% -470.4% Higher ROE DSGN
52-Week Range Position
Momentum
30% ($7–$17) 0% ($2–$8) Stronger Trend DSGN
Beta / 30D Volatility
Risk Regime
1.32β · 61% Vol 1.67β · 79% Vol Lower Realized Risk DSGN
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 38.2 / 100 (SELL) Higher Composite DSGN
Trailing 12M Revenue (USD)
Operating Scale
$33,000 $64M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 30.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$59M ($13M Net Cash) $6.0M EBITDA (-470.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FHTX +1.43 pp
DSGN: -3.59% · FHTX: -2.16%
3M Horizon DSGN +38.28 pp
DSGN: -34.91% · FHTX: -73.19%
6M Horizon DSGN +45.52 pp
DSGN: -7.1% · FHTX: -52.62%
1Y Horizon DSGN +99.28 pp
DSGN: +40.79% · FHTX: -58.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DSGN vs FHTX. Trailing 12-month operating profitability (DSGN 0.0% vs FHTX 8.0%) and valuation multiples (DSGN N/M vs FHTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DSGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$33,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-36.9% · N/M
FHTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$64M
Gross Margin30.7%
Op. Margin8.0%
ROE / Fwd P/E-470.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DSGN BREAKDOWN
139d in phase · OBV NEUTRAL
Current IV 92.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FHTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 164.9%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FHTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DSGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FHTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $122.9M market capitalization and 8.0% operating margin.
OpEx & R&D Reinvestment 22.7% of Rev ($15M)
90D Engineering Disclosures 0 Published

Investor FAQ DSGN vs FHTX Key Questions & Quantitative Answers

As of Nov 16, 2026, Design Therapeutics, Inc. (DSGN) captures the overall head-to-head institutional edge over Foghorn Therapeutics Inc. (FHTX) on higher Unified Composite conviction (49.9/100 HOLD vs. 38.2/100 SELL) after splitting the core matrix 5–4 (led by composite factor balance), while FHTX wins 6–0 across the 6-pillar growth and valuation breakdown. DSGN trades at $9.94 (N/M Forward P/E, 0.0% operating margin) versus FHTX at $1.81 (N/M Forward P/E, 8.0% operating margin). Growth vs. Quality Trade-Off: DSGN earns the overall head-to-head edge with a stronger Unified Composite Score (49.9/100 HOLD vs. FHTX 38.2/100 SELL) and 1.32β · 61% Vol risk profile, whereas FHTX leads top-line expansion (+924.7% YoY revenue growth, N/M PEG, and 6 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile FHTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FHTX leads the Growth & Scale pillar: DSGN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with FHTX at +924.7% YoY revenue growth and +0.0% YoY earnings growth on $64M TTM revenue (30.7% gross margin, 8.0% operating margin). On trailing 12-month operating scale, DSGN generates $33,000 in USD-normalized revenue versus $64M for FHTX. In operating R&D and SG&A reinvestment, DSGN deploys N/A (0 90-day corporate R&D disclosures) versus 22.7% of Rev ($15M) (0 disclosures) for FHTX.

FHTX screens cheaper on headline valuation multiples. DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FHTX trades at N/M Forward P/E, 22.8x Trailing P/E, N/M PEG, and 1.9x EV/Revenue (9.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DSGN (-36.9% ROE) versus FHTX (-470.4% ROE) capital efficiency.

In options market volatility and institutional positioning, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk). By comparison, FHTX carries 164.9% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.67β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.